Tag Board
200

Эрүүл мэнд

Лавлагаа

Ëàâëàãàà
1.     Í. Íàðàíáàò áà áóñàä "Ìîíãîë óëñàä á¿ðòãýãäñýí áàéãàà õ¿íèé õàëäâàðò ºâ÷íèé ºíãºðñºí, îäîî, èðýýä¿éí òºëºâ áàéäàë”, ÓÁ õîò, 2008 îí, õóóäàñ 8-12
2.     ÄÝÌÁ "Çîíõèëîí òîõèîëääîã õàëäâàðò ºâ÷íèé òàíäàëò” ÓÁ õîò, 2004 îí, õóóäàñ 47-49
3.     ß.Äàãâàäîðæ íàð "Õàëäâàðò ºâ÷èí” ÓÁ õîò, 2003 îí, õóóäàñ 141-148
4.     Á.Ãàíáààòàð "Àíàãààõ óõààíû áè÷èë àìü ñóäëàë” ÓÁ õîò, 2009 îí, õóóäàñ 193-197
5.     ÕªÑ¯Ò "Õàëäâàðò ºâ÷íèé òóëãàìäñàí àñóóäàë” èëòãýëèéí õóðààíãóé, Óª õîò, 2008 îí, õóóäàñ 19-22
References
1.     Pollard AJ, Nadel S, Ninis N, Faust SN, Levin M. Emergency management of meningococcal disease: eight years on. Arch Dis Child. Apr 2007;92(4):283-6. [Medline].
2.     Pathan N, Faust SN, Levin M. Pathophysiology of meningococcal meningitis and septicaemia. Arch Dis Child. Jul 2003;88(7):601-7. [Medline].
3.     Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. Aug 9 2001;345(6):408-16. [Medline].
4.     Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. Jan 17 2004;363(9404):203-9. [Medline].
5.     Pathan N, Williams EJ, Oragui EE, Stephens AC, Levin M. Changes in the interleukin-6/soluble interleukin-6 receptor axis in meningococcal septic shock. Crit Care Med. Aug 2005;33(8):1839-44. [Medline].
6.     El Bashir H, Laundy M, Booy R. Diagnosis and treatment of bacterial meningitis. Arch Dis Child. Jul 2003;88(7):615-20. [Medline].
7.     Ortega-Sanchez IR, Meltzer MI, Shepard C, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis. Jan 1 2008;46(1):1-13. [Medline].
8.     Health Protection Agency. Invasive meningococcal infections, England and Wales, laboratory reports: weeks 51-52/2007. http://hpa.org.uk: 2008. [Full Text].
9.     Welch SB, Nadel S. Treatment of meningococcal infection. Arch Dis Child. Jul 2003;88(7):608-14. [Medline].
10.   Jansen AG, Sanders EA, VAN DER Ende A, et al. Invasive pneumococcal and meningococcal disease: association with influenza virus and respiratory syncytial virus activity?. Epidemiol Infect. Nov 2008;136(11):1448-54. [Medline].
11.   Faber J, Henninger N, Finn A, Zenz W, Zepp F, Knuf M. A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. Acta Paediatr. Mar 2009;98(3):548-52. [Medline].
12.   Darton T, Guiver M, Naylor S, Jack DL, Kaczmarski EB, Borrow R. Severity of meningococcal disease associated with genomic bacterial load. Clin Infect Dis. Mar 1 2009;48(5):587-94. [Medline].
13.   [Guideline] Health Protection Agency. Guidance for the public health management of meningococcal disease in the UK. [Full Text].
14.   Food and Drug Administration. Ceftriaxone (marketed as Rocephin) information. 2008. [Full Text].
15.   Roche. Important clarification of prescribing information. Contraindications. http://www.rocheusa.com. Available at http://www.rocheusa.com/products/rocephin/rocephin-hcp-letter.pdf. Accessed August 5, 2008.
16.   Medicines and healthcare products regulatory agency. Ceftriaxone; incompatibility with calcium containing solutions. http://www.nelm.nhs.uk/en/: 2008.
17.   Food and Drug Administration. Ceftriaxone (marketed as Rocephin) Information. http://www.fda.gov: April 2009. [Full Text].
18.   Cathie K, Levin M, Faust SN. Drug use in acute meningococcal disease. Arch Dis Child Educ Pract Ed. Oct 2008;93(5):151-8. [Medline].
19.   Levin M, Quint PA, Goldstein B, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet. Sep 16 2000;356(9234):961-7. [Medline].
20.   Derkx B, Wittes J, McCloskey R. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis. Apr 1999;28(4):770-7. [Medline].